Hacked: Hacking Finance

Stock Picks

Stock Pick: Novavax can be a Big Winner in 2017

Posted on .

Stock Pick: Novavax can be a Big Winner in 2017

Introduction

This article was posted on Saturday, 16:20, UTC.

Novavax (NASDAQ:NVAX) develops vaccines based on protein nanoparticles which can help increase the immune response in patients. It is currently awaiting results of phase 3 trial. A successful result will provide significant bump to the stock and also make it an attractive acquisition target by bigger pharmaceutical companies. RSV F maternal vaccine candidate in phase 3 Data from RSV F vaccine in phase 3 will show its efficacy. We should see the results by the second half of this year. If the results are excellent it will allow Novavax to target 4 million people. The market opportunity of this vaccine…

// -- Discuss and ask questions in our community on Workplace. Don't have an account? Send Jonas Borchgrevink an email -- //

To continue reading you need to be a Gold Member or Platinum Member. Let us help you become financially independent by signing up. You will get access to exclusive stories, analysis, and guides by experienced traders, economists, and entrepreneurs. Learn more about us here.

Log In Join Now for $39 a Month! OR Save $69 by Subscribing for a Year!

Important: Never invest money you can't afford to lose. Always do your own research and due diligence before placing a trade. Read our Terms & Conditions here.



Feedback or Requests?

Receive New Posts on Email:



Rohit Chatwal

Rohit Chatwal

Navigation
Weekly Recap Asset Current Value Weekly Change S&P 500 2345…